Tepezza hearing-loss claims have no finalized settlement as of mid-2026, but attorneys commonly project individual values in the range of about $140,000 to $500,000 for cases with favorable facts — permanent hearing loss carrying the highest amounts and isolated tinnitus the lower end. This Tepezza hearing loss settlement calculator estimates a payout from your hearing-injury severity, medical bills, lost wages, and a pain-and-suffering multiplier. Tepezza (teprotumumab) is an infusion drug approved for thyroid eye disease; lawsuits allege the manufacturer failed to warn that it can cause permanent hearing loss and tinnitus.
The federal Tepezza cases are consolidated in MDL 3079 in the U.S. District Court for the Northern District of Illinois, against Horizon Therapeutics (now part of Amgen). Plaintiffs allege the drug's label did not adequately warn patients and doctors about the risk of hearing damage. As of spring 2026 the docket included a few hundred pending actions, with bellwether trial proceedings underway and no global settlement reached — so all values are projections based on the alleged injuries and comparable litigation, not a published matrix.
Because no global Tepezza settlement exists yet, attorneys project values by combining the severity of the hearing injury with traditional damage math — economic damages (medical evaluation, hearing aids, and lost wages) plus non-economic damages for the permanent loss of hearing or constant tinnitus. The severity of the auditory injury, and whether it is permanent, is the dominant driver, which is why the calculator anchors to a hearing-injury tier.
Tepezza Estimate = Hearing-Injury Anchor + Economic Damages + Pain & Suffering (medical × multiplier)
The strongest claims involve permanent, documented hearing loss confirmed by audiometric testing, ideally with baseline and post-treatment audiograms showing a decline after Tepezza infusions. Cases of significant permanent loss with tinnitus fall in the middle, while isolated tinnitus or milder symptoms anchor the lower tiers. The actual value will ultimately depend on bellwether outcomes and any settlement matrix the parties negotiate — the projections here are an educational guide.
| Item | Detail |
|---|---|
| Drug | Tepezza (teprotumumab) for thyroid eye disease |
| Defendant | Horizon Therapeutics (now Amgen) |
| Litigation | MDL 3079, N.D. Illinois |
| Alleged injury | Permanent hearing loss and tinnitus |
| Status (mid-2026) | Bellwether phase, no global settlement |
Suppose a patient develops significant permanent hearing loss with tinnitus after several Tepezza infusions (Tier 2). She has $20,000 in medical and hearing-aid costs, $15,000 in lost wages, and a multiplier of 4. Economic damages are $35,000 and pain-and-suffering is $80,000 (medical × 4), but because the formula falls below the Tier 2 anchor, the calculator raises the estimate to the tier floor and displays a likely range. A tinnitus-only case would instead land near the Tier 4 anchor.
A Tepezza claim begins with confirming you received Tepezza infusions and have documented hearing loss or tinnitus that began during or after treatment. An attorney gathers the infusion records, audiometric testing (ideally baseline and follow-up), and proof of economic losses, then files into MDL 3079 or preserves the claim. Because the litigation is in the bellwether phase, individual cases generally await the outcome of the test trials and any negotiated settlement framework before resolving. Until then, the value of a claim is an informed projection based on its injury severity and the strength of its causation evidence.
Tepezza cases are handled on contingency, commonly 33% to 40% (mass-tort fees may be limited by the court), plus case costs such as audiology experts and records. Health insurers, Medicare, or Medicaid may assert liens for related care, repaid from any recovery but often negotiable. The figure this calculator estimates is a gross projection; your net recovery would be what remains after fees, costs, and liens. If a settlement program is established, its administrator will apply the agreed grid and deductions.
Under IRS Publication 4345, compensatory damages for a personal physical injury or physical sickness — including permanent hearing loss from a medication — are generally excluded from taxable income. Interest and any punitive component are taxable, and amounts allocated to non-physical claims may be treated differently. Confirm the tax treatment of any eventual settlement with a qualified tax professional.
This calculator is for patients who received Tepezza (teprotumumab) infusions for thyroid eye disease and developed hearing loss or tinnitus they attribute to the drug. It is especially useful for those with audiometric documentation showing a decline after treatment. Because the litigation is still developing, the tool is meant to help patients understand how severity and proof shape potential value — not to predict a specific outcome. If you have a Tepezza-related hearing injury, the tool frames a realistic projected range to discuss with counsel.
No Tepezza settlement is finalized as of mid-2026, so all figures are attorney projections, commonly cited around $140,000 to $500,000 for favorable cases. Permanent hearing loss confirmed by audiometry anchors the highest values; isolated tinnitus anchors the lower end. Baseline and post-infusion audiograms are the strongest causation evidence, and bellwether outcomes in MDL 3079 will shape any eventual settlement. The estimate this tool produces is a gross projection before fees, costs, and liens. Use it as an educational starting point and let a qualified attorney evaluate your specific claim.
No Tepezza settlement has been finalized as of mid-2026, so any figure is a projection. Attorneys commonly estimate favorable cases in the range of about $140,000 to $500,000, with permanent, profound hearing loss at the high end and isolated tinnitus at the lower end. Actual values will depend on bellwether outcomes and any negotiated settlement framework.
The lawsuits allege that Horizon Therapeutics (now part of Amgen) failed to adequately warn patients and doctors that Tepezza (teprotumumab), an infusion drug for thyroid eye disease, can cause permanent hearing loss and tinnitus. The federal cases are consolidated in MDL 3079 in the Northern District of Illinois.
As of mid-2026, there is no global Tepezza settlement. The litigation is in the bellwether phase, where representative cases are prepared and tried to help the parties gauge value. A settlement framework, if one is reached, would typically follow bellwether results. Until then, claim values are projections, not promises.
The strongest evidence is audiometric testing — ideally a baseline audiogram before treatment and a follow-up showing a decline after Tepezza infusions. Infusion records confirming the drug and timing, plus documentation of the onset of hearing loss or tinnitus during or shortly after treatment, strengthen causation.
Tinnitus can be part of a Tepezza claim, but cases with isolated tinnitus and no measurable hearing loss are generally projected at the lower end of the value range, while documented permanent hearing loss carries higher projections. An attorney evaluates whether your specific symptoms and proof fit the litigation criteria.
Compensatory damages for a physical injury or sickness, including permanent hearing loss, are generally not taxable under IRS Publication 4345. Interest and any punitive damages are taxable, and amounts allocated to non-physical claims may be treated differently. Confirm any eventual settlement's treatment with a tax professional.